deltatrials

Schizophrenia Trials in Marietta, United States

Conditions / Schizophrenia / Marietta, United States

Schizophrenia is a medical condition with active clinical research programs worldwide.

22 total trials for this combination

Showing top 10 of 22 trials

Trials

NCT ID Title Status Phase
NCT01714713 A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy COMPLETED PHASE3
NCT02970305 Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE) COMPLETED PHASE2
NCT00528905 Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia COMPLETED PHASE2
NCT01432444 Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole COMPLETED PHASE3
NCT05304767 An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia RECRUITING PHASE3
NCT05859698 Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia COMPLETED PHASE4
NCT03893825 A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia COMPLETED PHASE3
NCT01716975 Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy COMPLETED PHASE3
NCT05145413 A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia COMPLETED PHASE3
NCT07105111 A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor RECRUITING

Related Pages